These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

850 related items for PubMed ID: 26872110

  • 1. Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.
    Franceschet I, Cazzagon N, Del Ross T, D'Incà R, Buja A, Floreani A.
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):508-13. PubMed ID: 26872110
    [Abstract] [Full Text] [Related]

  • 2. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
    Rossi RE, Conte D, Massironi S.
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):123-31. PubMed ID: 26636407
    [Abstract] [Full Text] [Related]

  • 3. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
    Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM, International PSC Study Group.
    Gastroenterology; 2017 Jun; 152(8):1975-1984.e8. PubMed ID: 28274849
    [Abstract] [Full Text] [Related]

  • 4. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
    Fevery J, Van Steenbergen W, Van Pelt J, Laleman W, Hoffman I, Geboes K, Vermeire S, Nevens F.
    Aliment Pharmacol Ther; 2016 Mar; 43(5):612-20. PubMed ID: 26748470
    [Abstract] [Full Text] [Related]

  • 5. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.
    Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, Nydegger A, Vavricka SR, Moradpour D, Schoepfer AM, Swiss IBD Cohort Study Group.
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):91-97. PubMed ID: 27622999
    [Abstract] [Full Text] [Related]

  • 6. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, Faubion W, Fell J, Gold BD, Griffiths A, Koletzko S, Kugathasan S, Markowitz J, Ruemmele FM, Veereman G, Winter H, Masel N, Shin CR, Tang KL, Thayu M.
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [Abstract] [Full Text] [Related]

  • 7. [Primary sclerosing cholangitis].
    Boonstra K, Ponsioen CI, Rauws EA, Beuers U.
    Ned Tijdschr Geneeskd; 2010 Jun; 154():A1476. PubMed ID: 20619015
    [Abstract] [Full Text] [Related]

  • 8. Prevalence of inflammatory bowel disease among patients with primary sclerosing cholangitis in Iran.
    Hadizadeh M, Abedi SH, Malekpour H, Radinnia E, Jabbehdari S, Padashi M, Zali MR, Mohammad Alizadeh AH.
    Arab J Gastroenterol; 2016 Mar; 17(1):17-9. PubMed ID: 27032493
    [Abstract] [Full Text] [Related]

  • 9. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Tse CS, Loftus EV, Raffals LE, Gossard AA, Lightner AL.
    Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
    [Abstract] [Full Text] [Related]

  • 10. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
    Bayraktar Y, Arslan S, Saglam F, Uzunalimoglu B, Kayhan B.
    Hepatogastroenterology; 1998 Jul; 45(24):2064-72. PubMed ID: 9951867
    [Abstract] [Full Text] [Related]

  • 11. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J.
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [Abstract] [Full Text] [Related]

  • 12. Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey.
    Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B.
    J Clin Gastroenterol; 2001 Oct; 33(4):299-301. PubMed ID: 11588543
    [Abstract] [Full Text] [Related]

  • 13. Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study.
    Erichsen R, Olén O, Sachs MC, Pedersen L, Halfvarson J, Askling J, Ekbom A, Ludvigsson JF, Sørensen HT.
    Cancer Epidemiol Biomarkers Prev; 2021 May; 30(5):886-894. PubMed ID: 33627380
    [Abstract] [Full Text] [Related]

  • 14. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.
    Zheng HH, Jiang XL.
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):383-90. PubMed ID: 26938805
    [Abstract] [Full Text] [Related]

  • 15. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O.
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
    [Abstract] [Full Text] [Related]

  • 16. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Rocha HC, Vilela EG.
    Gastroenterol Hepatol; 2022 Feb; 45(2):83-90. PubMed ID: 34023469
    [Abstract] [Full Text] [Related]

  • 17. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
    Everhov ÅH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Söderling J, Ekbom A, Neovius M, Ludvigsson JF, Askling J, Olén O.
    Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
    [Abstract] [Full Text] [Related]

  • 18. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease.
    Manninen P, Karvonen AL, Laukkarinen J, Aitola P, Huhtala H, Collin P.
    Scand J Gastroenterol; 2015 Apr; 50(4):423-8. PubMed ID: 25636976
    [Abstract] [Full Text] [Related]

  • 19. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
    Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A.
    J Hepatol; 2010 Aug; 53(2):313-7. PubMed ID: 20472317
    [Abstract] [Full Text] [Related]

  • 20. Cancer Risk and Surveillance in Primary Sclerosing Cholangitis.
    Folseraas T, Boberg KM.
    Clin Liver Dis; 2016 Feb; 20(1):79-98. PubMed ID: 26593292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.